✦ LIBER ✦

Quantitative determination of the biological activity of botulinum toxin type A by measuring the compound muscle action potential (CMAP) in rats

✍ Scribed by Takashi Sakamoto; Yasushi Torii; Motohide Takahashi; Setsuji Ishida; Yoshitaka Goto; Hirotoshi Nakano; Tetsuhiro Harakawa; Akihiro Ginnaga; Shunji Kozaki; Ryuji Kaji

Book ID: 116922500
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 236 KB
Volume: 54
Category: Article
ISSN: 0041-0101
DOI: 10.1016/j.toxicon.2009.06.020

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Quantification of potency of neutralizin

Quantification of potency of neutralizing antibody to botulinum toxin by measuring the compound muscle action potential (CMAP)

✍ Torii Yasushi; Goto Yoshitaka; Takahashi Motohide; Sakamoto Takashi; Harakawa Te 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 39 KB

Quantitative determination of biological

Quantitative determination of biological activity of botulinum toxins utilizing compound muscle action potentials (CMAP), and comparison of neuromuscular transmission blockage and muscle flaccidity among toxins

✍ Yasushi Torii; Yoshitaka Goto; Motohide Takahashi; Setsuji Ishida; Tetsuhiro Har 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 291 KB

The effect of botulinum toxin type a inj

The effect of botulinum toxin type a injection on compound muscle action potential in an in vivo rat model

✍ John V. Cichon Jr.; Thomas V. Mccaffrey; William J. Litchy; Joost L. Knops 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 441 KB

Biological activity of botulinum toxin t

Biological activity of botulinum toxin type A in the chronically implanted rat

✍ Cheryl L. Rainey; Robert E. Stone Jr; David L. Zealear 📂 Article 📅 1995 🏛 SAGE Publications 🌐 English ⚖ 117 KB

The variability in the clinical effect i

The variability in the clinical effect induced by botulinum toxin type A: The role of muscle activity in humans

✍ Dr. R. Eleopra; V. Tugnoli; D. de Grandis 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 648 KB

## Abstract When botulinum toxin (BT) is administered for the first time at fixed doses, variable clinical responses can be observed in patients with the same form of dystonic disorder. Many factors may contribute to this phenomenon, including the variability in the rate of absorption of the drug.